Skip to main content
ROQUEFORT THERAPEUTICS PLC logo

ROQUEFORT THERAPEUTICS PLC — Investor Relations & Filings

Ticker · ROQ ISIN · GB00BMDQ2T15 LEI · 254900P4SISIWOR9RH34 IL Professional, scientific and technical activities
Open in API
Filings indexed 182 across all filing types
Latest filing 2022-09-26 Director's Dealing
Country GB United Kingdom
Listing IL ROQ

About ROQUEFORT THERAPEUTICS PLC

https://www.roquefortplc.com/

Roquefort Therapeutics PLC is a biotechnology company focused on developing next-generation, first-in-class medicines for hard-to-treat cancers. The company operates within the high-growth immuno-oncology market. Its portfolio consists of five novel, patent-protected, pre-clinical anti-cancer programs. These programs are designed to target cancers that have become resistant to existing therapies. Roquefort Therapeutics utilizes a distributed R&D model, combining its in-house expertise and laboratory facilities with a network of partnerships with leading academic cancer research centers to advance its development strategy.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is an official announcement filed with RNS (RNS Number : 6760A) dated September 26, 2022. The content explicitly details a 'Director/PDMR Shareholding' transaction, specifically a 'Purchase' of ordinary shares by a Non-Executive Director (Dr Darrin M Disley). This type of filing, reporting personal share transactions by company directors and executives, directly corresponds to the definition of 'Director's Dealing'. The detailed table structure under 'NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES' confirms this classification. Therefore, the appropriate code is DIRS.
2022-09-26 English
Interim Results to 30 June 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Results to 30 June 2022' and contains comprehensive financial statements, including a Consolidated Statement of Comprehensive Income and a Consolidated Statement of Financial Position for the six-month period. It includes management commentary, a chairman's statement, and financial data, which fits the definition of an Interim/Quarterly Report (IR). It is not merely an announcement of a report, as it contains the actual financial data and statements. H1 2022
2022-09-23 English
Investor Presentation
Investor Presentation Classification · 98% confidence The document is a formal announcement disseminated via RNS (RNS Number: 6704Z) dated September 16, 2022. The title explicitly states 'Investor Presentation' and the body announces that executives will give a live presentation following an acquisition via the 'Investor Meet Company platform'. This content directly relates to providing information and scheduling a presentation for investors, which aligns perfectly with the definition of an Investor Presentation (IP). Although it is distributed via RNS, the specific content is about an investor presentation, making 'IP' the most accurate classification over the general 'RNS' fallback.
2022-09-16 English
Board and Management Appointments
Board/Management Information Classification · 99% confidence The document is clearly identified as an RNS (Regulatory News Service) announcement, indicated by the 'RNS Number' header and the concluding boilerplate text stating, 'This information is provided by RNS, the news service of the London Stock Exchange.' The core content announces specific changes to the company's leadership structure: the appointment of an Executive Director/CEO, an Executive Director/CSO, a Non-Executive Director, and a Chief Medical Advisor, alongside the resignation of another director. This directly matches the definition for Board/Management Information (MANG). Although it is distributed via RNS, the primary subject matter is management appointments, making MANG the most specific and appropriate classification over the general RNS fallback.
2022-09-16 English
Acquisition Completion, Admission & Voting Rights
Regulatory Filings Classification · 98% confidence The document is an official announcement disseminated via RNS (Regulatory News Service) on September 16, 2022. The content details the completion of an acquisition (Oncogeni Limited), the admission of new shares to trading on the London Stock Exchange, and confirmation of the total voting rights. This type of announcement, which reports on corporate actions, share capital changes, and significant events via an official news service like RNS, fits best under the general 'Regulatory Filings' category, as it is not a specific financial report (like 10-K or IR) or a specific corporate action announcement like a dividend (DIV) or director dealing (DIRS). While it touches upon share capital changes (SHA) and major shareholding implications (MRQ), the primary function here is a broad regulatory update disseminated through the RNS system, making RNS the most appropriate general classification for this type of market disclosure.
2022-09-16 English
Roquefort Therapeutics plc - Single prospectus
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus prepared under the UK Prospectus Regulation Rules and approved by the Financial Conduct Authority (FCA). It relates to a placing of new ordinary shares, a proposed acquisition of Oncogeni Limited, and the admission of new shares to trading on the London Stock Exchange. The document includes detailed information such as risk factors, financial information, pro forma financials, taxation, and additional information. It is clearly a formal offering document for capital raising and acquisition purposes, which fits the definition of a Capital/Financing Update. It is not an annual report, earnings release, or any other report type but a prospectus related to share issuance and acquisition. Therefore, the correct classification is Capital/Financing Update (CAP). The document length and content confirm it is the full prospectus, not just an announcement or summary.
2022-09-15 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.